Innovating Works

CONSORZIO PER VALUTAZIONI BIOLOGICHE E F...

Desconocido
ERDERA: EUROPEAN RARE DISEASES RESEARCH ALLIANCE CONSORZIO PER VALUTAZIONI BIOLOGICHE E FARMACOLOGICHE participó en un HORIZON EUROPE: HORIZON-HLTH-2023-DISEASE-07 The European Rare Diseases Research Alliance (ERDERA) aims to improve the health and well-being of the 30 million people living with a rare...
2024-08-20 - 2031-08-31 | Financiado
ERAMET: Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the... CONSORZIO PER VALUTAZIONI BIOLOGICHE E FARMACOLOGICHE participó en un HORIZON EUROPE: HORIZON-HLTH-2023-IND-06 ERAMET will provide an integrated approach for developers and regulators’ decision-making for paediatric and orphan drugs, centred on the dr...
2023-11-17 - 2027-12-31 | Financiado
AMELIE: Anchored Muscle cELls for IncontinencE CONSORZIO PER VALUTAZIONI BIOLOGICHE E FARMACOLOGICHE participó en un H2020: H2020-SC1-BHC-2018-2020 Faecal incontinence (FI) is a common condition affecting ~67 million people in Europe, seriously impairing living and productivity of affect...
2020-05-06 - 2025-08-31 | Financiado
EJP RD: European Joint Programme on Rare Diseases CONSORZIO PER VALUTAZIONI BIOLOGICHE E FARMACOLOGICHE participó en un H2020: H2020-SC1-BHC-2018-2020 As recognized by the Council Recommendation 2009/C 151/02, rare diseases (RD) are a prime example of a research area that can strongly profi...
2018-12-13 - 2024-08-31 | Financiado
c4c: conect4children COllaborative Network for European Clinical Trials For Children CONSORZIO PER VALUTAZIONI BIOLOGICHE E FARMACOLOGICHE participó en un H2020: H2020-JTI-IMI2-2016-10-two-stage Paediatric medicines development is embedded in the European policy, legislation and in the work of the pharmaceutical industry but currentl...
2018-06-22 - 2025-04-30 | Financiado
ID-EPTRI: Infradev European Paediatric Translational Research Infrastructure CONSORZIO PER VALUTAZIONI BIOLOGICHE E FARMACOLOGICHE tramitó un H2020: H2020-INFRADEV-2016-2017 The general objective of this project is to design the framework for the European Paediatric Translational Research Infrastructure (EPTRI),...
2018-01-25 - 2020-04-30 | Financiado
PedCRIN: Paediatric Clinical Research Infrastructure Network CONSORZIO PER VALUTAZIONI BIOLOGICHE E FARMACOLOGICHE participó en un H2020: H2020-INFRADEV-2016-2017 Children’s health is a major societal challenge for Europe and the world, requiring development of paediatric medicines and treatments strat...
2016-12-14 - 2021-06-30 | Financiado
SMART: SMART Small Medicines Advanced Research Training CONSORZIO PER VALUTAZIONI BIOLOGICHE E FARMACOLOGICHE participó en un H2020: H2020-TWINN-2015 SMART Project is aimed to raise IPCZD staff’s research profile and increase capacity in providing innovative paediatric research methods suc...
2015-12-02 - 2018-12-31 | Financiado
DEEP: DEferiprone Evaluation in Paediatrics CONSORZIO PER VALUTAZIONI BIOLOGICHE E FARMACOLOGICHE tramitó un FP7: β-thalassaemia major is one of the most severe forms of chronic congenital anaemia. The recommended treatment consists in regular blood tran...
Financiado
GAPP: GAbapentin in Paediatric Pain CONSORZIO PER VALUTAZIONI BIOLOGICHE E FARMACOLOGICHE tramitó un FP7: Chronic pain is estimated to affect 15-20% of children with varying disabilities. Due to the paucity of clinical information and appropriate...
Financiado
GRIP: Global Research in Paediatrics CONSORZIO PER VALUTAZIONI BIOLOGICHE E FARMACOLOGICHE participó en un FP7: Paediatric drugs (PD) lack appropriate testing. Most drugs have inadequate information about dosing regimen, dose adjustment and how to admi...
Financiado
NEOVANC: Treatment of late onset bacterial sepsis caused by vancomycin susceptible bacteria in neonates and i... CONSORZIO PER VALUTAZIONI BIOLOGICHE E FARMACOLOGICHE participó en un FP7: Vancomycin is the critically important antibiotic to treat neonatal Late Onset Sepsis (LOS) due to Gram positive bacteria in neonates, inclu...
Financiado
NEOMERO: European multicenter network to evaluate pharmacokinetics safety and efficacy of Meropenem in neona... CONSORZIO PER VALUTAZIONI BIOLOGICHE E FARMACOLOGICHE participó en un FP7: Previous studies have demonstrated the high frequency of bacterial sepsis in neonates and infants admitted to neonatal intensive care unit (...
Financiado
RESPECT: Relating Expectations and needs to Participation and Empowerment of children in Clinical Trials CONSORZIO PER VALUTAZIONI BIOLOGICHE E FARMACOLOGICHE participó en un FP7: There are two objectives for this project, firstly to clarify the expectations and needs of children and their families who have participate...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.